The University of Chicago Header Logo

Connection

Russell Z. Szmulewitz to Quinolines

Back to Details
This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Quinolines.
Russell Z. Szmulewitz
Connection Strength
0.152
Quinolines
  1. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926.
    View in: PubMed
    Score: 0.152
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.